Anbio Biotechnology Class A (NNNN) Cash Flow Statement
Where NNNN’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$6.7M −423.9% vs 2024
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$6.7M −77.9% margin
- Returned to shareholders
- —
- Change in cash
- −$4.0M cash at year-end $7.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
NNNN operating cash flow, capex and free cash flow
NNNN cash flow trends, 2021–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $4.2M2021 | −$6.7M2025 | — | |
| Capital expenditures | $02021 | $02025 | — | |
| Free cash flow | $4.2M2021 | −$6.7M2025 | — | |
| Free cash flow margin | 94.4%2021 | −77.9%2025 | −172.4 pts | |
| Operating cash flow / net income | 1.652021 | −1.052025 | −2.70 | |
| Capex / revenue | 0.0%2021 | 0.0%2025 | 0.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NNNN cash flow by activity
NNNN net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
NNNN cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | $6.4M | $2.4M | $2.3M | $10.0M | $2.5M |
| Depreciation & amortization | — | $0 | $12,059 | $6,252 | $0 |
| Change in working capital | −$13.2M | $44,646 | −$1.2M | −$5.5M | $1.6M |
| Other non-cash items | $68,003 | −$337,101 | −$163,388 | −$38,885 | $0 |
| Cash from operating activities | −$6.7M | $2.1M | $898,367 | $4.4M | $4.2M |
| Investing activities | |||||
| Capital expenditures | $0 | $0 | $0 | −$3 | $0 |
| Investments (net) | −$4.2M | $337,101 | $1.7M | −$1.5M | $0 |
| Acquisitions & other investing | $0 | $0 | $0 | $3 | — |
| Cash from investing activities | −$4.2M | $337,101 | $1.7M | −$1.5M | — |
| Financing activities | |||||
| Shares issued | $7.2M | $0 | $0 | $0 | $0 |
| Other financing | −$282,550 | −$344,605 | −$42,835 | $0 | — |
| Cash from financing activities | $6.9M | −$344,605 | −$42,835 | $0 | — |
| Summary | |||||
| Net change in cash | −$4.0M | $2.1M | $2.6M | $2.9M | $4.2M |
| Cash at end of period | $7.8M | $11.8M | $9.7M | $7.1M | $4.2M |
| Free cash flow | −$6.7M | $2.1M | $898,367 | $4.4M | $4.2M |
| Free cash flow margin | −77.9% | 25.4% | 13.4% | 18.9% | 94.4% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating cash flow / net income | −1.05 | 0.88 | 0.40 | 0.44 | 1.65 |
| Dec '24 | Jun '24 | Dec '23 | Jun '23 | |
|---|---|---|---|---|
| Operating activities | ||||
| Net income | −$1.3M | $3.9M | $792,932 | $1.6M |
| Depreciation & amortization | — | — | $3,540 | $9,494 |
| Change in working capital | $3.1M | −$3.1M | −$2.0M | $668,348 |
| Other non-cash items | −$209,641 | −$149,344 | −$157,434 | −$17,681 |
| Cash from operating activities | $1.6M | $647,541 | −$1.3M | $2.3M |
| Investing activities | ||||
| Capital expenditures | −$2 | −$0 | −$1 | −$1 |
| Acquisitions & other investing | $215,572 | $149,344 | $160,697 | $1.7M |
| Cash from investing activities | $215,570 | $149,344 | $160,696 | $1.7M |
| Financing activities | ||||
| Shares issued | $0 | $0 | $0 | $0 |
| Other financing | −$248,893 | −$124,142 | $230,082 | −$276,414 |
| Cash from financing activities | −$248,893 | −$124,142 | $230,082 | −$276,414 |
| Summary | ||||
| Net change in cash | $1.6M | $672,743 | — | $3.7M |
| Cash at end of period | $12.6M | $11.4M | $10.7M | $3.7M |
| Free cash flow | $1.6M | $647,541 | −$1.3M | $2.3M |
| Free cash flow margin | 63.5% | 10.2% | −33.7% | 69.7% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating cash flow / net income | — | 0.17 | −1.68 | 1.40 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
NNNN cash generation
In fiscal 2025 (ended December 31, 2025), Anbio Biotechnology generated -$6.7 million of cash from operations (down 423.9%) and spent $0 on capital expenditures, leaving free cash flow of -$6.7 million, −77.9% of revenue. Cash and equivalents fell by $4.0 million over the year.
Related: NNNN income statement, NNNN balance sheet. See the NNNN stock overview for the latest quote and news.
NNNN cash flow FAQ
What is Anbio Biotechnology's free cash flow?
Anbio Biotechnology's free cash flow was -$6.7 million in fiscal 2025: -$6.7 million of operating cash flow minus $0 of capital expenditures It was $2.1 million a year earlier..
How much cash does Anbio Biotechnology generate from operations?
Anbio Biotechnology generated -$6.7 million of cash from operating activities in fiscal 2025, −1.05 times its net income of $6.4 million.